Healthscope Ltd announces full-year results: Here's what you need to know

Healthscope Ltd (ASX:HSO), the biggest IPO in four years, delivered its first lot of full-year results today since listing on the ASX.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

What: Healthscope Ltd (ASX: HSO) shares have dropped 2.5 cents or 1.1% today despite the company meeting guidance for its full year ending 30 June 2014.

The company which is Australia's second largest private hospital operator, reported a full-year net loss of $19.3 million (beating prospectus forecast of $145.1 million) thanks to lower net financial costs as well as operating earnings of $357.3 million, which were slightly above its prospectus forecast.

So What: Over the course of the year, Healthscope continued to benefit from Australia's favourable healthcare environment. With an ageing population, increased medical treatment capabilities as well as high levels of private healthcare insurance across the nation, the company managed to grow revenue by an impressive 5.1% on FY13 to $2.33 billion. Pleasingly, this also translated into strong earnings growth with margins improving and EBITDA increasing by 9% to $357.3 million.

In particular, the group's Hospitals and International Pathology divisions provided the boost for revenues. Its Hospitals division, which comprises 79% of the company's EBITDA, grew revenues by 5.5%, while revenue from its International Pathology division grew 17.6% on FY2013 to $224.2 million.

Healthscope will continue to strengthen its Hospitals segment over the coming years with a number of redevelopments underway. These include the Knox Private Hospital in Victoria, Gold Coast Private Hospital, Norwest and National Capital Private Hospital.

Now What: While Australia's healthcare sector remains an attractive industry to invest in, I would be reluctant to purchase shares of Healthscope until its shares cool down in price a little. At this stage, I would be more inclined to invest in Healthscope's larger rival Ramsay Health Care Limited (ASX: RHC) which not only pays a dividend but also boasts strong growth prospects in the Asian market.

Motley Fool contributor Ryan Newman does not own shares in any of the companies mentioned.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »